Preparation of arginine&amp;ndash;glycine&amp;ndash;aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

Chang, Che Yi; Wang, Ming Chen; Miyagawa, Takuya; Chen, Zhi Yu; Lin, Feng Huei; Chen, Ko Hua; Liu, Guei‐Sheung; Tseng, Ching Li

doi:10.2147/ijn.s114754

Cited by 41 publications

(35 citation statements)

References 43 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the carboxylate-associated peaks at approximately 1,610 cm −1 and 1,410 cm −1 overlapped with the peaks of gelatin and EGCG. 26,40 Therefore, a similar FTIR pattern of GEH and GE was revealed ( Figure 2B).…”

Section: Resultssupporting

confidence: 54%

“…EGCG and NPs were synthesized by a previously described self-assembly method with slight modifications. 26 Type A gelatin and EGCG solution were mixed by magnetic stirring using the same volume (1 mL) and concentration (4.4 mg/mL). The self-assembly of the two components to yield GE ( Figure 1A) occurred during the mixing.…”

Section: Preparation Of Gelatin-egcg Nps With Ha Decorationmentioning

confidence: 99%

See 1 more Smart Citation

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Huang

Wang

Chen

et al. 2018

IJN

Self Cite

View full text Add to dashboard Cite

IntroductionDry-eye syndrome (DES) is a general eye disease. Eye drops are the common ophthalmological medication. However, the ocular barrier makes it difficult to attain high drug bioavailability. Nanomedicine is a promising alternative treatment for ocular diseases and may increase drug content in the affected eye.MethodsTo explore this potential, we constructed nanoparticles (NPs) containing an anti-inflammatory agent for DES treatment. The NPs were made of gelatin–epigallocatechin gallate (EGCG) with surface decoration by hyaluronic acid (HA) and designated “GEH”. The particle size, surface charge, and morphology were evaluated. The in vitro biocompatibility and anti-inflammation effect of nanoparticles were assayed via culturing with human corneal epithelium cells (HCECs) and in vivo therapeutic effect was examined in a DES rabbit’s model.ResultsThe synthesized GEH NPs had a diameter of approximately 250 nm and were positively charged. A coculture experiment revealed that 20 µg/mL GEH was not cytotoxic to HCECs and that an EGCG concentration of 0.2 µg/mL downregulated the gene expression of IL1B and IL6 in inflamed HCECs. Large amounts of GEH NPs accumulated in the cytoplasm of HCECs and the ocular surfaces of rats and rabbits, indicating the advantage of GEH NPs for ocular delivery of medication. Twice-daily topical treatment with GEH NPs was performed in a rabbit model of DES. The ocular surface of GEH-treated rabbits displayed normal corneal architecture with no notable changes in inflammatory cytokine levels in the cornea lysate. The treatment improved associated clinical signs, such as tear secretion, and fluorescein staining recovered.ConclusionWe successfully produced GEH NPs with high affinity for HCECs and animal eyes. The treatment can be delivered as eye drops, which retain the drug on the ocular surface for a longer time. Ocular inflammation was effectively inhibited in DES rabbits. Therefore, GEH NPs are potentially valuable as a new therapeutic agent delivered in eye drops for treating DES.

show abstract

Section: Resultssupporting

confidence: 54%

Section: Preparation Of Gelatin-egcg Nps With Ha Decorationmentioning

confidence: 99%

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Huang

Wang

Chen

et al. 2018

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epigallocatechin gallate-loaded cationic lipid nanoparticles have been reported to exhibit promising effects to mitigate ocular inflammation and oxidative stress, which revealed the probable effectiveness of epigallocatechin-3-gallate in diabetic complications [290]. In addition, self-assembled gelatin-epigallocatechin gallate nanoparticles were found to inhibit ocular angiogenesis remarkably via targeting integrin αvβ3 [291]. The aforementioned reports predicted that the efficacious roles of catechins nanoformulations against diabetes and associated complications.…”

Section: Catechinsmentioning

confidence: 95%

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

Dewanjee

Chakraborty

Mukherjee

et al. 2020

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is a life-threatening metabolic syndrome. Over the past few decades, the incidence of diabetes has climbed exponentially. Several therapeutic approaches have been undertaken, but the occurrence and risk still remain unabated. Several plant-derived small molecules have been proposed to be effective against diabetes and associated vascular complications via acting on several therapeutic targets. In addition, the biocompatibility of these phytochemicals increasingly enhances the interest of exploiting them as therapeutic negotiators. However, poor pharmacokinetic and biopharmaceutical attributes of these phytochemicals largely restrict their clinical usefulness as therapeutic agents. Several pharmaceutical attempts have been undertaken to enhance their compliance and therapeutic efficacy. In this regard, the application of nanotechnology has been proven to be the best approach to improve the compliance and clinical efficacy by overturning the pharmacokinetic and biopharmaceutical obstacles associated with the plant-derived antidiabetic agents. This review gives a comprehensive and up-to-date overview of the nanoformulations of phytochemicals in the management of diabetes and associated complications. The effects of nanosizing on pharmacokinetic, biopharmaceutical and therapeutic profiles of plant-derived small molecules, such as curcumin, resveratrol, naringenin, quercetin, apigenin, baicalin, luteolin, rosmarinic acid, berberine, gymnemic acid, emodin, scutellarin, catechins, thymoquinone, ferulic acid, stevioside, and others have been discussed comprehensively in this review.

show abstract

“…eyedrops were used to deliver SKlB1002 onto the ocular surface, which have great advantage over the traditional subconjunctival injection because it is noninvasive and easily accepted by the patients. However, tear screening and nasolacrimal duct drainage may affect the bioavailability of SKLB1002 (30,31). To overcome this flaw, CMC-Na was used as the solvent of the eyedrops to increase the retention time of SKlB1002.…”

Section: Discussionmentioning

confidence: 99%

SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in�vitro and ocular angiogenesis in�vivo

et al. 2020

View full text Add to dashboard Cite

ocular angiogenesis is a major cause of severe vision loss, which can affect several parts of the eye, including the retina, choroid and cornea. Vascular endothelial growth factor receptor 2 (VeGFr2) inhibitors have demonstrated great potential for treating ocular angiogenesis and SKlB1002 is a potent inhibitor of VeGF receptor 2 signaling. The present study investigated the effects of SKlB1002 administration on ocular angiogenesis. SKlB1002 administration did not show obvious cytotoxicity and tissue toxicity at the tested concentrations. in an alkali-burn corneal model, SKlB1002 administration significantly decreased the mean length and number of new corneal blood vessels. SKlB1002 administration significantly reduced endothelial cell proliferation, migration and tube formation in vitro. Mechanistically, SKlB1002 inhibited endothelial angiogenic functions by blocking the phosphorylation of erK1/2, JnK and p38. Thus, selective inhibition of VeGFr-2 through SKlB1002 administration is a promising therapy for ocular angiogenesis.

show abstract

Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

Cited by 41 publications

References 43 publications

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in�vitro and ocular angiogenesis in�vivo

Contact Info

Product

Resources

About

Preparation of arginine&ndash;glycine&ndash;aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

Cited by 41 publications

References 43 publications

Gelatin&ndash;epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Gelatin&ndash;epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in�vitro and ocular angiogenesis in�vivo

Contact Info

Product

Resources

About

Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief